34 related articles for article (PubMed ID: 35248490)
21. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
22. Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy.
Montagna E; Bagnardi V; Viale G; Rotmensz N; Sporchia A; Cancello G; Balduzzi A; Galimberti V; Veronesi P; Luini A; Mastropasqua MG; Casadio C; Sangalli C; Goldhirsch A; Colleoni M
Ann Oncol; 2015 Feb; 26(2):307-13. PubMed ID: 25411418
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
24. Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer-Treated with Neoadjuvant Systemic Therapy.
De Schepper M; Nguyen HL; Richard F; Rosias L; Lerebours F; Vion R; Clatot F; Berghian A; Maetens M; Leduc S; Isnaldi E; Molinelli C; Lambertini M; Grillo F; Zoppoli G; Dirix L; Punie K; Wildiers H; Smeets A; Nevelsteen I; Neven P; Vincent-Salomon A; Larsimont D; Duhem C; Viens P; Bertucci F; Biganzoli E; Vermeulen P; Floris G; Desmedt C
Cancer Res Commun; 2024 Jan; 4(1):186-199. PubMed ID: 38147006
[TBL] [Abstract][Full Text] [Related]
25. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
26. Changes in Ki-67 in Residual Tumor and Outcome of Primary Inflammatory Breast Cancer Treated With Trimodality Therapy.
Song Z; Li C; Zhou D; Liu J; Qian X; Zhang J
Clin Breast Cancer; 2022 Jul; 22(5):e655-e663. PubMed ID: 35248490
[TBL] [Abstract][Full Text] [Related]
27. What is the best treatment recommendation for HER2+ IBC with residual disease?-a narrative review.
Zakon DB; Valero V
Chin Clin Oncol; 2021 Dec; 10(6):59. PubMed ID: 35016513
[TBL] [Abstract][Full Text] [Related]
28. Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis.
Li L; Han D; Wang X; Wang Q; Tian J; Yao J; Yuan L; Qian K; Zou Q; Yi W; Zhou E; Yang K
Future Oncol; 2017 May; 13(11):1021-1034. PubMed ID: 28088868
[TBL] [Abstract][Full Text] [Related]
29. Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.
Tarantino P; Ajari O; Graham N; Vincuilla J; Parker T; Hughes ME; Tayob N; Garrido-Castro AC; Morganti S; King TA; Mittendorf EA; Curigliano G; Lin NU; Tolaney SM
Eur J Cancer; 2024 Apr; 201():113920. PubMed ID: 38368741
[TBL] [Abstract][Full Text] [Related]
30. Update on systemic treatment for newly diagnosed inflammatory breast cancer.
Chainitikun S; Saleem S; Lim B; Valero V; Ueno NT
J Adv Res; 2021 Mar; 29():1-12. PubMed ID: 33842000
[TBL] [Abstract][Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
